ATE472528T1 - 2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen - Google Patents

2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen

Info

Publication number
ATE472528T1
ATE472528T1 AT05848578T AT05848578T ATE472528T1 AT E472528 T1 ATE472528 T1 AT E472528T1 AT 05848578 T AT05848578 T AT 05848578T AT 05848578 T AT05848578 T AT 05848578T AT E472528 T1 ATE472528 T1 AT E472528T1
Authority
AT
Austria
Prior art keywords
dinor
methylene
skin
compound
homopregnacalciferol
Prior art date
Application number
AT05848578T
Other languages
German (de)
English (en)
Inventor
Hector Deluca
Rafal Barycki
Lori Plum
Margaret Clagett-Dame
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE472528T1 publication Critical patent/ATE472528T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05848578T 2004-11-22 2005-11-18 2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen ATE472528T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63018204P 2004-11-22 2004-11-22
PCT/US2005/042030 WO2006057932A2 (en) 2004-11-22 2005-11-18 2-METHYLENE-18,19-DINOR-1α-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES

Publications (1)

Publication Number Publication Date
ATE472528T1 true ATE472528T1 (de) 2010-07-15

Family

ID=36215592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05848578T ATE472528T1 (de) 2004-11-22 2005-11-18 2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen

Country Status (11)

Country Link
US (1) US7238681B2 (enExample)
EP (1) EP1817278B1 (enExample)
JP (1) JP5043674B2 (enExample)
AT (1) ATE472528T1 (enExample)
AU (1) AU2005309747A1 (enExample)
CA (1) CA2588417C (enExample)
DE (1) DE602005022098D1 (enExample)
ES (1) ES2349662T3 (enExample)
MX (1) MX2007006544A (enExample)
NZ (1) NZ555280A (enExample)
WO (1) WO2006057932A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
JPWO2009116557A1 (ja) * 2008-03-21 2011-07-21 富士フイルム株式会社 薬剤含有組成物
US20110237557A1 (en) * 2010-03-23 2011-09-29 Deluca Hector F Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
US8604009B2 (en) * 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
US8420839B1 (en) 2011-10-05 2013-04-16 Wisconsin Alumni Research Foundation Crystallization of 1α-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol
EP2746252A1 (en) * 2012-12-21 2014-06-25 Wisconsin Alumni Research Foundation (WARF) Crystallization of 1alpha-hydroxy-2-methylene- 18,19-dinor-homopregnacalciferol
AU2012268858B2 (en) * 2012-12-21 2017-03-09 Wisconsin Alumni Research Foundation Crystallization of 1a-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
AU7544501A (en) 2000-09-08 2002-03-22 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
ATE346839T1 (de) * 2002-03-29 2006-12-15 Wisconsin Alumni Res Found Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacal iferol
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
WO2005051323A2 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment

Also Published As

Publication number Publication date
NZ555280A (en) 2010-12-24
EP1817278B1 (en) 2010-06-30
US7238681B2 (en) 2007-07-03
CA2588417A1 (en) 2006-06-01
US20060122157A1 (en) 2006-06-08
CA2588417C (en) 2012-09-18
EP1817278A2 (en) 2007-08-15
WO2006057932A3 (en) 2006-08-03
DE602005022098D1 (de) 2010-08-12
AU2005309747A1 (en) 2006-06-01
JP5043674B2 (ja) 2012-10-10
JP2008520716A (ja) 2008-06-19
WO2006057932A2 (en) 2006-06-01
MX2007006544A (es) 2007-07-25
ES2349662T3 (es) 2011-01-10

Similar Documents

Publication Publication Date Title
DE60215225D1 (de) Alpha-hydroxy-2-methylen-10-nor-pregnacalciferol und seine anwendungen
PT1315504E (pt) 1-alfa-hidroxi-2-metileno-19-nor-homopregnacalciferol e suas aplicacoes terapeuticas
MX2007006263A (es) Analogos 2a-metil y 2??-metil de 19,26,27-trinor-(20s)-1a- hidroxivitamina d3 y sus usos.
ATE552239T1 (de) 2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga
WO2006057899A3 (en) 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
DE602005021245D1 (de) 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
MX2009003241A (es) Analogos de 2-metilen-(20r,25s)-19,27-dinor-(22e)-vitamina d.
MX2007006262A (es) 2-metilen-19-nor-1a-hidroxi-17-en homopregnacalciferol y sus usos.
DE60229430D1 (de) (20s)-1 alpha-hydroxy-2-methylen-19-nor-bishomopregnacalciferol und ihre verwendungen
MX2010007264A (es) Análogos de vitamina d 2-metilen-(20s, 25r)-19, 26-dinor.
ATE472528T1 (de) 2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen
ATE552238T1 (de) 2-methylen-(20s,25s)-19,27-dinor-(22e)-vitamin- - analoga
WO2006057902A3 (en) 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
WO2009086439A3 (en) 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs
ATE496885T1 (de) 1-alpha-hydroxy-2-(3'-hydroxypropyliden)-19-nor vitamin-d-verbindungen mit einer 1,1- dimethylpropyl-seitenkette

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties